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The ﬂagellated protozoa Trypanosoma cruzi is the causal agent of Chagas’ disease, a signiﬁcant public health issue and still a
major cause of morbidity and mortality in Latin America. Acute Chagas’ disease elicits a strong inﬂammatory response. In
order to control the parasite multiplication, cells of the monocytic lineage are highly mobilized. Monocyte diﬀerentiation leads
to the formation of phagocytosing macrophages, which are strongly activated and direct host defense. A distinguishing feature
of Chagas’ disease-triggered macrophages is the presence of increased numbers of distinct cytoplasmic organelles termed lipid
bodies or lipid droplets. These organelles are actively formed in response to the parasite and are sites for synthesis and storage
of inﬂammatory mediators. This review covers current knowledge on lipid bodies elicited by the acute Chagas’ disease within
inﬂammatory macrophages and discusses the role of these organelles in inﬂammation. The increased knowledge of lipid bodies in
pathogenic mechanisms of infections may not only contribute to the understanding of pathogen-host interactions but may also
identify new targets for intervention.
1.Introduction
The ﬂagellated protozoa Trypanosoma cruzi is the causal
agent of Chagas’ disease (aka American trypanosomiasis)
discovered at the beginning of the twentieth century by the
Brazilian physician Carlos Chagas [1]. This disease remains
a major problem with a great impact on public health in the
LatinAmerica.Chagas’diseaseaﬀectsnearly8millionpeople
and 28 million people are at risk of acquiring the disease in
15 endemic countries of Latin America [2]. Unfortunately,
there is no vaccine available to prevent Chagas’ disease [3].
T. cruzi is transmitted to humans primary through the
feces of triatomine insects, at bite sites or in mucosa, through
blood transfusion or orally through contaminated food. The
parasite then invades the bloodstream and lymphatic system,
and becomes established in the muscle and cardiac tissue,
digestive system, and phagocytic cells [4]. T. cruzi may also
be transmitted from mother to child across the placenta and
through the birth canal, thus causing abortion, prematurity,
and organic lesions in the fetus [4].
Chagas’ disease is characterized by an acute phase with
or without symptoms, and with entry point signs (inoc-
ulation chagoma or Roma˜ na’s sign), fever, adenomegaly,
hepatosplenomegaly, evident parasitemia, and an indetermi-
nate chronic phase (asymptomatic, with normal results from
electrocardiogram and X-ray of the heart, esophagus, and
colon) or with a cardiac, digestive, or cardiac-digestive form
[4].Thefactorsthatdeterminethedistinctclinicaloutcomes,
leading to a mild or to a severe form of the disease, are not
completelyunderstood.Infact,themostintriguingchallenge2 Mediators of Inﬂammation
to understanding the pathophysiology of Chagas disease still
lies in the complex host-parasite interrelationship (reviewed
in [5]).
The parasite has an obligate intracellular, proliferative,
nonﬂagellate form, called amastigote. After many division
cycles, the amastigote forms convert into a ﬂagellate form,
the infective trypomastigote. Due to the high number of
parasites into the host cell cytoplasm, the cell membrane dis-
rupts and the infection spreads, aﬀecting diﬀerent organs
(reviewed in [4, 6]).
Acute Chagas’ disease elicits a strong inﬂammatory
response.Inordertocontroltheparasitemultiplication,cells
of the monocytic lineage are highly mobilized (Figure 1).
There is an intense migration and extravasation of mono-
cytes from the bloodstream into target organs, mainly the
heart (Figures 1 and 2). Monocyte diﬀerentiation leads to
the formation of phagocytosing macrophages, strongly acti-
vated and involved in inhibiting parasite replication in the
myocardiumandothertissues[7,8](Figure1).Theabilityof
activated macrophages to process and present antigens, pro-
duce cytokines, and provide costimulatory signals demon-
strates their pivotal role in initiating immune responses. The
importanceofthesecellstothehostdefensehasbeenpointed
out by us and other groups during the in vivo acute T. cruzi
infection in both humans and experimental models [7–10].
Because macrophages are key players in the initial resis-
tance to the T. cruzi infection, a better understanding of their
responses to the parasite is hence crucial for the develop-
ment of appropriate therapeutic interventions and Chagas’
disease control. A distinguishing feature of Chagas’ disease-
triggered macrophages is the presence of increased numbers
of distinct cytoplasmic organelles termed lipid bodies (aka
lipid droplets) [11]. Lipid bodies are lipid-rich organelles
found in small numbers in most eukaryotic cells as roughly
spherical organelles, comprised of an outer monolayer of
phospholipids, a core containing neutral lipids, and variable
protein composition. In contrast to other organelles, lipid
bodies lack, therefore, a delimiting unit membrane structure
(reviewed in [12]). Analysis of the fatty acid composition of
the phospholipids revealed that they are structurally distinct
from the phospholipids of the rough endoplasmic reticulum
(ER) and from cholesterol/sphingolipid-rich microdomains.
Unique features of lipid bodies include the abundance of
unsaturated fatty acids in lyso-phosphatidylcholine and the
relative abundance of phosphatidylcholine with 2 mono-
unsaturated acyl chains [13]. The hydrophobic core of lipid
bodies is occupied by triacylglycerols, diacylglycerols, retinyl
esters,freecholesterol,andcholesterolestersinvariousratios
depending on the cell type [14–16].
Leukocyte lipid bodies contain several functionally di-
verse types of proteins, including structural proteins, meta-
bolic enzymes, and kinases. Lipid body-speciﬁc struc-
tural proteins, the PAT family of proteins—Perilipin, adi-
pose-diﬀerentiation-related protein (ADRP) [17] and tail-
interacting protein of 47kDa (TIP47) [18]—are found at
the circumferential rim of lipid bodies. Moreover, a number
of small GTPases of the Rab family, considered critical
regulators of vesicular traﬃc and organelle interaction, and
a variety of other proteins are described in lipid bodies
[17, 19, 20].
In the past, lipid bodies were largely associated with
lipid storage, but it is now recognized that lipid bodies are
dynamic and functionally active organelles linked to diverse
biological functions, such as lipid metabolism, cell signaling,
and membrane traﬃcking (reviewed in [12, 21]). Lipid body
has also been associated to immunoregulatory function in a
number of human inﬂammatory diseases including inﬂam-
matory arthritis [22], acute respiratory distress syndrome
[23], hypereosinophilia syndrome [24], and mycobacterial
infection [25, 26], in addition to be related to neoplasic
and emerging metabolic diseases, such as atherosclerosis,
diabetes, and obesity (reviewed in [27, 28]).
Since the ﬁrst report on lipid body formation in response
to the in vivo acute T. cruzi infection by our group in
2003 [11], we have been investigating these organelles as
key players in the host-parasite interaction and markers of
macrophage activation during infectious diseases [6, 29–
31]. This review covers current knowledge on lipid bodies
triggered by the acute Chagas’ disease within inﬂammatory
macrophages and discusses the role of these organelles in
inﬂammation. The increased knowledge of lipid bodies in
pathogenic mechanisms of infections may not only con-
tribute to the understanding of pathogen-host interactions
but may also identify new targets for intervention [12, 29,
31].
2.Trypanosoma cruzi Induction of
Lipid Body Formation
Althoughaccumulationoflipidbodieshasbeendocumented
for nearly 30 years in leukocytes and other cells in diﬀer-
ent inﬂammatory diseases [22–24, 32], the observation of
lipid body formation in response to an in vivo infectious
disease dates to 2003 [11]. By investigating inﬂammatory
macrophages from rats infected with a virulent strain of
T. cruzi (Y strain), it was observed a signiﬁcant increase
of the lipid body numbers in peritoneal macrophages at
day 6 and 12 of the infection. While control peritoneal
macrophages presented ∼2.19 ± 0.4 (mean ± SEM) lipid
bodies/macrophage, peritoneal macrophages from infected
animals showed ∼18.09 ± 1.4 at day 12 of infection [11].
In vitro, lipid body accumulation has been observed
within peritoneal macrophages isolated from mice and cul-
tured with T. cruzi for 24h [35] (Figures 3(a)–3(d)). At
this time of infection, both the cells containing internal-
ized parasites as well nonparasitized cells show increased
number of lipid bodies compared to control, noninfected
cells, suggesting a bystander ampliﬁcation of the response
(Figure 3(b)). Interestingly, parasitized cells show signiﬁcant
higher number of lipid bodies (threefold) compared to
nonparasitizedcells,indicatingthattheuptakeoftheparasite
directly induces formation of lipid bodies [35] (Figure 3(b)).
D’Avila and colleagues have also demonstrated that lipid
body formation in macrophages in response to the T. cruzi
infection occurs through a Toll-like receptor-2- (TLR2-)Mediators of Inﬂammation 3
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Figure 1: Activation of heart inﬂammatory macrophages during the acute infection with Trypanosoma cruzi. In response to acute infections,
a cascade of events recruits cells derived from monocytic lineage from the peripheral blood into heart. This cascade culminates in a
strong activation of macrophages. Classical activation of macrophages involves the key cytokine interferon gamma (IFN-γ)a n dT. cruzi
components (GPI anchors and CpG-rich DNA). These parasite products are recognized at the macrophage surface by Toll-like receptors
(TLRs)-2 and 9, respectively. These receptors are a class of pattern recognition receptors (PRRs), which initiate an immune response and
directly activates macrophages. Additionally, TLR-2 can heterodimerizate either TLR1 or TLR6 to recognize T. cruzi GPI anchors [33]. TNF-
α is one of the most eﬃcient activators of macrophages to a trypanocidal function. PAMPS, pathogen-associated molecular patterns; GPI,
glycosylphosphatidylinositol;TNF-α,tumornecrosisfactor-alpha;MIP-1α,macrophageinﬂammatoryproteinα;MCP-1/CCL-2,monocyte
chemoattractant protein-1; IP-10, inducible protein 10.
dependent mechanism, demonstrating a mechanism involv-
ing surface receptors in this event [35].
As noted, the accumulation of newly recruited macro-
phages in the heart is one of the main ﬁndings of the
acute T. cruzi infection and it is correlated with the intense
myocardium parasitism which occurs during the early infec-
tion in both experimental models and humans (reviewed
in [6]) (Figure 2). At day 12 of T. cruzi infection in rats,
is observed the most intense inﬂammatory process and
parasitism in the heart compared to other points during the
acute phase [7]. Ultrastructural analysis of this organ
showednumerousinﬁltratingmacrophageswithlipidbodies
prominentlyincreasedinnumberandsize[11](Figure4(a)).
Inﬂammatory heart macrophages, evaluated by quantitative
electron microscopy, exhibited a mean of 8.3lipid bodies/cell
section (range of 1–25) at the same time of infection whereas
control noninﬂammatory macrophages showed a mean of
2.6lipid bodies/cell section (range of 0–3) [11].
One intriguing aspect of lipid bodies is their osmio-
philia, which is dependent on the cell type and can
change during elicited inﬂammatory responses (reviewed in
[12]). In inﬂammatory macrophages, the lipid body den-
sity can consistently change during pathogen infections,
as revealed by ultrastructural studies [29, 31]. Based on
osmiophilia, lipid bodies were identiﬁed and quantitated
as light-dense, electron-dense, and strongly electron-dense
organelles within inﬂammatory macrophages from diﬀerent
origins, mainly from the heart [29]. T. cruzi infection
induces a signiﬁcant increase in the numbers of light-
dense lipid bodies compared to noninfected controls which
show lipid bodies preferentially as electron- dense organelles
(Figure 4(a)). Of note, lipid bodies change consistently their
osmiophilia in macrophages stimulated in vivo with higher
parasite load in irradiated-infected rats. These animals were
exposed to a single, high dose of gamma irradiation 1 day
before infection, which depletes the humoral and cellular4 Mediators of Inﬂammation
My
(a)
My
My
(b)
A
V
A
C
C
C
V
A
A
A
∗
(c)
Figure 2: Morphological aspects of the heart from noninfected and infected rats at 12 days of infection with Trypanosoma cruzi.( a )
Histological view of the myocardium from an uninfected rat. In (b), nests of amastigotes (arrows), the intracellular form of the parasite, and
inﬂammatory processes (circles) characterized by predominance of mononuclear cells are observed in the myocardium (My). Semi-serial
5μm-thicksectionsoftheheartwerecut,stainedbyhaematoxylinandeosinandexaminedforqualitativeevaluationoftheinﬂammatoryand
degenerative processes and quantiﬁcation of parasitism [8, 34]. In (c), an electron micrograph of a parasitized cardiomyocyte (c) showing
vacuoles (V) and many amastigotes (A). Data are representative of three independent experiments. Four to six rats per group. Panel (a) was
reprinted from [9] with permission. Scale bar, 15μm( a ,b ) ;1μm( c ) .
immune responses except for the phagocytic activity of
macrophages. Inﬂammatory macrophages from irradiated-
infected animals show an increase in the numbers of both
light-dense and strongly electron-dense lipid bodies com-
pared to infection alone [29] (Figures 4(b) and 4(c)).
Lipid body morphological changes, including alterations in
osmiophilia, may reﬂect diﬀerences in lipid composition,
stages of formation of new lipid bodies, mobilization, and/
or neutral lipids/phospholipids ratio within lipid bodies.
In addition, these morphological changes highlight lipid
bodies as dynamic organelles, able to consistently change
their structure in concert with cell activation [29]. In fact,
lipid bodies in activated macrophages can be imaged as
heterogeneous organelles, with lucent areas, granular, and/
or membranous internal structures [29]. Of interest, by
proteomic and ultrastructural studies, we have deﬁned lipid
bodies as organelles with internal endoplasmic reticulum-
(ER-) like membranes and ER luminal proteins, suggesting
a model by which enveloped ER-membranes and domains
form lipid bodies [19].
Another morphological feature of lipid bodies is their
considerable size variation. For example, in scoring the
diameters of lipid bodies within macrophages from rats
experimentally infected with T. cruzi, 74% of lipid bodiesMediators of Inﬂammation 5
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Figure 3: Trypanosoma cruzi infection induces macrophage lipid body formation. Peritoneal macrophages isolated from mice were cultured
or not with T. cruzi and the formation of lipid bodies analyzed after 24h by staining with BODIPY 493/503 (a and b), a ﬂuorescent lipid
probe for highly hydrophobic environments [35] or osmium tetroxide (c and d). While uninfected cells (a, c) have small number of lipid
bodies, infected cells (b and d) show increased number of these organelles. Lipid bodies are seen as green (a and b) or brownish (c and d),
roundorganelles.Nuclei ofmacrophages andinternalized parasites(arrows)were stainedwithDAPI(4 ,6-diamidino-2-phenylindole;blue).
Scale bar, 10μm.
had size <0.5μm in noninfected whereas 54% of lipid
bodies from infected animals were >0.5μm, reaching up to
3μm (Figure 4(c)). Increase of the parasite burden induced
by gamma irradiation triggered signiﬁcant formation of
large lipid bodies within inﬂammatory macrophages, with
diameters around 4μm[ 29]. These ﬁndings reveal that not
only the number but also the osmiophilia and size of lipid
bodies represent structural indicatives of the participation of
these organelles in innate immune responses [29].
Accumulation of lipid bodies within macrophages has
also been documented during other infectious diseases, for
example, during the progression of tuberculosis caused by
Mycobacterium tuberculosis in both humans and experimen-
tal settings [25, 36] and in the course of leprosy, caused
by Mycobacterium leprae [37]. In experimental studies with
Mycobacterium bovis bacillus Calmette-Gu´ erin (BCG), it was
found that this pathogen is capable of inducing a dose- and
time-dependentincreaseonLBformationwithinpleuraland
peritoneal macrophages [31, 38].
In addition to inducing lipid body formation [11], the
infection with T. cruzi elicits a close interaction of lipid
bodies with phagosomes within macrophages and even an
apparent translocation of lipid bodies into these vacuoles,
suggesting a discharge of the lipid body content [29]. How-
ever, the meaning of this interaction is still unknown. The
lipid body-phagosome association as well as the internal-
ization of lipid bodies by phagosomes during the acute T.
cruzi infection may represent diﬀerent stages of phagosome
maturation leading to killing of the parasite or favor the
parasite survival [29].6 Mediators of Inﬂammation
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Figure 4: Lipid bodies (LB) within heart inﬂammatory macrophages increase in size in response to acute Trypanosoma cruzi infection and
parasite load. (a) Strongly electron dense LBs from an infected animal are observed in the cytoplasm n conjunction with free amastigote
forms of the parasite (asterisks). In (b), a giant LB is seen close to the nucleus in an irradiated-infected rat. (c) LB diameter variation
in diﬀerent groups. A signiﬁcant increase of LB occurred in infected alone compared to uninfected and in irradiated-infected compared
to infected alone groups (P<0.05). Before infection, rats were irradiated or not and heart samples processed for transmission electron
microscopy at day 12 of infection. Scale bar, 1.0μm (a); 600nm (b). Reprinted from [29] with permission.
The lipid body-phagosome association has also been
observed in cells infected with other pathogens such as
M. bovis BCG [31], M. tuberculosis [39], and Chlamydia
trachomatis [40]. It remains to be established if it represents
a strategy for pathogen replication or if has implications for
pathogen outcome.
3. LipidBody and Inﬂammation
As noted, accumulation of lipid bodies has been observed
in the cytoplasm of activated cells associated with varied
inﬂammatory and infectious conditions, both in clinical and
experimental situations [23, 26, 31, 35, 36, 41, 42].
Lipid bodies are recognized sites for localization of
arachidonic acid, the precursor for the synthesis of inﬂam-
matory mediators (eicosanoids) and eicosanoid-forming
enzymes such as cyclooxygenases (COX) and lipoxygenases
(LO) (reviewed in [12, 43]). The production of eicosanoids
has been demonstrated during T. cruzi infection and both
leukotrienes and prostaglandins seem to play a role in
the pathogenesis of Chagas’ disease. Macrophages, the ﬁrst
line of defense, are important sources for prostaglandin E2
(PGE2) production during T. cruzi infection [44–46]a n dMediators of Inﬂammation 7
parasite-induced lipid body formation within macrophages
is accompanied by enhanced COX-2 expression [35]. In
fact, by using ﬂuorescence microscopy, it was demon-
strated that T. cruzi-infected macrophages were found to be
positive COX-2. The immunostaining appeared punctuate
throughout the cytoplasm, suggesting that COX-2 may be
localized within lipid bodies, in addition to the conventional
perinuclear membrane localization. Colocalization of COX-
2 and adipose diﬀerentiation-related protein (ADRP), a
recognized marker for lipid bodies [47, 48], conﬁrmed the
presence of this enzyme within lipid bodies [35].
The increased formation of lipid bodies within inﬂam-
matory macrophages is accompanied by signiﬁcant pro-
duction of the PGE2. The highest numbers of lipid bodies
induced by the T. cruzi infection in inﬂammatory macro-
phages occurred in parallel to the highest production of
PGE2 [11] (Figure 5). This increase was documented at days
6 (fourfold) and 12 (sixfold) after infection in rats [11]
(Figure 5). In murine model, the increased PGE2 production
derived from lipid bodies was rapidly observed at 24h of
infection (fourfold), through a TLR2-dependent manner
[35].
Prostaglandins down modulate a number of macrophage
functions. Prostaglandins lead to reduced proinﬂammatory
cytokine secretion, decreased antigen presentation, and
diminished production of free radicals in these cells [49–
52]. Studies have been demonstrating that prostaglandins
arepotent inhibitors oftumor necrosis factor-alpha(TNF-α)
synthesis and act as deactivators of macrophage trypanocidal
function [46, 53]. Moreover, high levels of PGE2 favor T.
cruzi replication and the treatment of the infected mice with
nonsteroidal anti-inﬂammatory drugs (NSAIDs), inhibitors
of COX-2 enzyme, signiﬁcantly reduces parasite replication
[35, 44, 54]. Interestingly, addition of exogenous PGE2 is
also able to increase replication of the parasite Leishmania
amazonensis in macrophages, indicating that PGE2 increases
intracellular load of this pathogen in susceptible mice [55].
In contrast to inﬂammatory macrophages, peripheral
blood monocytes from T. cruzi-infected animals show low
number of lipid bodies [11]. The maturation of peripheral
blood monocytes to tissue macrophages followed by activa-
tion of these cells is likely involved in lipid body formation
and eicosanoid release during Chagas’disease [11].
Eicosanoids may also be directly observed within lipid
bodies. By using a newly developed strategy, the Eicosacell
methodology [56], which directly detects the eicosanoid
synthesis in situ, intracellular sites of newly formed PGE2
colocalized with ADRP-labeled lipid bodies, conﬁrming that
lipid bodies are sites of compartmentalization of PGE2
synthesis during T. cruzi infection [35].
During the T. cruzi infection, the role of prostaglandins
in the outcome of the parasite is still a matter of debate.
It has been shown that the widely used nonsteroidal anti-
inﬂammatory drugs (NSAIDs), aspirin (an inhibitor of
both constitutive COX-1 and inducible COX-2) [57]a n d
indomethacin (a preferential inhibitor of COX-1) [57],
inhibit PGE2 synthesis and are able to control parasitaemia
in susceptible mice [44]. Likewise, aspirin and NS-398
(COX-2 inhibitor) [58]) were able to modulate lipid body
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Figure 5: Trypanosoma cruzi infection induces concomitant lipid
body formation and prostaglandin E2 (PGE2) synthesis. Associa-
tions between number of lipid bodies (bars) and prostaglandin E2
(PGE2)p e r i t o n e a ll e v e l s( l i n e )i nr a t sa td a y6o r1 2o fi n f e c t i o n
with T. cruzi and in uninfected controls. At both days, the lipid
body numbers were signiﬁcantly increased (P<0.05) in parallel
to an accentuated increase of PGE2 synthesis. Data are expressed as
means ± SEM. Reprinted from [11] with permission.
formation and consequently to inhibit the PGE2 production
andparasitegrowthinmacrophages[35].Thesedatasupport
the concept that T. cruzi induces and exploits host-derived
lipid bodies to extend and maintain its own survival. More-
over, pharmacologic intervention of lipid body biogenesis
inhibitsT.cruzisurvivalandreplicationinmacrophages,and
therefore these organelles may act as potentially targets for
therapy during the acute phase of Chagas’ disease [35].
4.LipidBody andApoptosis during
T. cruzi Infection
Apoptosis of host cells, mostly lymphocytes and cardiomy-
ocytes, has been identiﬁed during the T. cruzi infection in
both humans and experimental models and seem to play an
important immune regulatoryrolein this andother parasitic
infections [44, 59, 60].
Uptake of apoptotic bodies, a process termed eﬀero-
cytosis, is able to impact on host inﬂammatory mediator
production and susceptibility to infection [44, 60, 61]. It
was recently demonstrated that eﬀerocytosis may aﬀect lipid
body formation and PGE2 synthesis during the T. cruzi
infection [35] (Figure 6). These authors showed that the
uptake of apoptotic cells, but not living or necrotic cells by
cultured macrophages, triggers lipid body formation in the
absence of infection. However, when infected macrophages
are exposed to apoptotic cells, the eﬀerocytosis process
ampliﬁes the eﬀects of the parasite on lipid body formation
leading to a higher lipid body accumulation compared to
noninfected cells exposed to apoptotic bodies (Figure 6).8 Mediators of Inﬂammation
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Figure 6: Uptake of apoptotic cells by macrophages induces lipid body formation and PGE2 synthesis during Trypanosoma cruzi infection.
LB formation (a) and prostaglandin E2(PGE2) synthesis (b) by mice macrophages infected in vitro with T. cruzi alone or co-cultured with
apoptotic cells for 24 hours. Each bar represents the mean ± standard error of the mean (SEM) from 50 consecutively counted macrophages
from at least 4 independent pools of 3 animals each. Statistically signiﬁcant (P # 0.05) diﬀerences between control and infected or stimulated
groups are indicated by asterisks; Mφ, macrophages. In (c), a large typical apoptotic body (outlined in red in (ci)) showing very condensed,
electron-dense nuclear chromatin and degenerating mitochondria (red arrowheads) is seen within a heart macrophage of a rat with 12 days
of infection. Note that the apoptotic body is surrounded by several lipid bodies with distinct electron densities. Rats were infected with the Y
strain of T. cruzi and the myocardium processed for transmission electron microscopy at day 12 of the acute infection. Reprinted from [35]
with permission. Scale bar, 1μm.
Consistent with the lipid body function in inﬂammation, as
discussed in Section 3, the uptake of apoptotic cells by both
infected and noninfected macrophages induces increased
lipid body-derived PGE2 synthesis. Interestingly, 24h after
the uptake of apoptotic cells by noninfected macrophages,
newly formed lipid bodies show in situ both COX-2 and
PGE2, similarly to infected cells [35].
Freire de Lima and colleagues [44] demonstrated that
the recognition of apoptotic cells by the αvβ3 integrin
(vitronectin receptor) is decisive for apoptotic-cell cytoad-
herence and the induction of both PGE2 and transforming
growthfactorbeta(TGF-β)releaseduringT.cruziinfections.
The involvement of αvβ3 integrin on lipid body formation
and parasite replication induced by apoptotic cell uptake wasMediators of Inﬂammation 9
also evaluated utilizing ﬂavoridin, a desintegrin that blocks
binding of integrins αvβ3 [62]. Flavoridin blocked lipid body
formation and COX-2 expression, induced by incubation
of macrophages with apoptotic cells, indicating that the
engagementandactivationofαvβ3 issuﬃcienttotriggerlipid
body biogenesis, COX-2 expression, and enhanced PGE2
synthesis in macrophages [35].
Distinct works have been demonstrating that TGF-β is
consistently produced during the T. cruzi infection [35, 63,
64].Moreover,asnoted,theinteractionofmacrophageswith
apoptoticcellsleadsmacrophagestoproduceTGF-β andalso
renders phagocytic cells more permissive to T. cruzi infection
[35, 63–65]. A recent report showed that TGF-β induces
lipid body formation, aﬀecting in turn the PGE2 release,
and making phagocytic cells more permissive to T. cruzi
infection [35]. In fact, in conjunction with increased lipid
bodyformationandPGE2 production,infectedmacrophages
presented exacerbated parasite replication when cocultured
with apoptotic cells for 24 hours [35]. The capacity of other
cytokines to modulate lipid body formation in macrophages
during the T. cruzi infection remains to be deﬁned.
As mentioned in Section 3, aspirin and NS-398 inhibit
cyclooxygenase production. Likewise, these drugs are able to
inhibit lipid body formation in infected macrophages in the
presence or absence of apoptotic cells, suppresses apoptotic
cell eﬀects on lipid body-derived PGE2 production, and
reverses the eﬀects of apoptotic cells on parasite replication
[35]. Accordingly, the fatty acid synthase inhibitor C75 sig-
niﬁcantly inhibited lipid body formation induced by T. cruzi,
with or without the presence of apoptotic cells. Strikingly, it
was demonstrated that the treatment with C75, in parallel
to lipid body inhibition, reversed the parasite replication
induced by apoptotic cells [35]. In summary, macrophage
lipid bodies formed during T. cruzi infection in association
withapoptoticcellstimulationdirectlyimpactthecapacityof
macrophages to produce increased amounts of PGE2,w h i c h
may have impact on the ability of the host to control the
infection.
5. FinalRemarks
In recent years, the association of lipid bodies, morpholog-
ically distinct organelles, with many potential roles in cells,
in both health and disease, has brought special attention to
them. Lipid body accumulation has been documented in
varied inﬂammatory situations, in both experimental and
human conditions [12, 25, 66].
Research over the last decade has identiﬁed an important
formation of lipid bodies within inﬂammatory macrophages
in response to the T. cruzi-host interaction. Newly formed
lipid bodies during Chagas’ disease and other inﬂamma-
tory diseases are notable for their capacity to synthesize
inﬂammatory mediators, such as PGE2 and for expressing
enzymes linked to this synthesis, such as COX-2 [12, 21].
Lipid bodies elicited by T. cruzi and other pathogens are
now recognized not only as inﬂammatory organelles and
structural markers of pathogen-induced cell activation, but
also as organelles able to modulate host cell processes [11,
29, 35]. For example, a recent work supports the concept
that T. cruzi induces and exploits host-derived lipid bodies
to extend and maintain its own survival [35]. However,
much remains to be learned. More work will be needed
to understand the inﬂuence of lipid bodies on the host
cell physiology and if these organelles have a major role
in the destruction or intracellular survival of the parasite.
The increased knowledge of lipid bodies in pathogenic
mechanisms of infections may not only contribute to the
understanding of pathogen-host interactions but may also
identify new targets for intervention.
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